(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -36.68% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Novavax's revenue in 2025 is $1,078,718,000.On average, 4 Wall Street analysts forecast NVAX's revenue for 2025 to be $167,885,833,981, with the lowest NVAX revenue forecast at $162,801,711,649, and the highest NVAX revenue forecast at $173,774,917,986. On average, 5 Wall Street analysts forecast NVAX's revenue for 2026 to be $78,854,734,118, with the lowest NVAX revenue forecast at $44,032,507,960, and the highest NVAX revenue forecast at $176,162,516,167.
In 2027, NVAX is forecast to generate $57,501,322,871 in revenue, with the lowest revenue forecast at $46,273,926,661 and the highest revenue forecast at $64,458,654,035.